Reading TELO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELO free→Reading TELO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELO free→QuarterlyIQ Insights · TELO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Chief Financial Officer — Alan Weichselbaum: The departure of the CFO without any stated disagreement and subsequent appointment of a fractional CFO.
Completion of Acquisition or Disposition of Assets The information contained in
Unregistered Sales of Equity Securities. The information contained in
Entry into a Material Definitive Agreement On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”). The Transaction was previously approved by the Company’s shareholders during the Company’s annual shareholders meeting on March 23, 2026. At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Co…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 23, 2026, at the Annual Meeting of the Shareholders of Telomir Pharmaceuticals, Inc. (the “Company”), the Company’s shareholders approved an amendment to the Company’s 2023 Omnibus Incentive Plan (the “Plan”) to (1) increase the number of shares reserved under the Plan from 6,500,000 to 11,500,000, and (2) to allow for the repricing of opt…
Other Events Telomir Pharmaceuticals Reports New Cellular Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity—without relying on cytotoxic mechanisms. On February 5, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) reported new findings from preclinical cellular studies evaluating its…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) submitted its preliminary proxy statement on Schedule 14A to the Securities and Exchange Commission (the “SEC”) in connection with its annual meeting of shareholders. At that time, the Company had planned to hold its annual meeting of shareholders on December 30, 2025, subject to completion of the SEC review process. The preli…
Other Events Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (the “Company”) is reporting results from a completed preclinical efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (“TNBC”). The study was conducted in collaboration with BioReperia using its ZTX® ONCOLEADS plat…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On December 15, 2025, the Compensation Committee of the Board of Directors of Telomir Pharmaceuticals, Inc. (the “Company”) approved certain short-term and long-term incentive actions for the Company’s Chief Executive Officer, Erez Aminov. These approvals were subsequently ratified by the full Board of Directors of the Company (the “Board”). The Com…
Departure of Directors or Certain Officers. Director Resignation On November 14, 2025, Craig Eagle, a member of the Board of Directors (the “Board”) of Telomir Pharmaceuticals Inc. (the “Company”), resigned from the Board, effective immediately. Mr. Eagle’s resignation was not as a result of any disagreement with the Company, the Company’s management, or any other member of the Board. The Board thanks Mr. Eagle for his service to the Company. A copy of the resignation letter provided by Mr. E…
Entry into a Material Definitive Agreement Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir’s foundation for partnerships, licensing, and long-term value creation . On October 17, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (“Telomir” or the “Company”) entered…
Other Events Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes—highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation. On August 7, 2025, Telomir Pharmaceutical…
Other Events Telomir Pharmaceuticals Reports Telomir-1 Demonstrates a Rare Mitochondrial Activity Profile by Selectively Restoring Energy and Improving Oxidative Balance in Diseased Human Cell Lines Without Causing Them to Divide Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) today reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchin…
Entry into a Material Definitive Agreement. The information set forth in
Unregistered Sales of Equity Securities. The information set forth in
Unregistered Sales of Equity Securities. The information set forth in
Other Events Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1’s upcoming IND submission for a rare disease indication On May 19, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (the “Company”) raised $3 million in equity financing through a direct investment by The Bayshore Trust, an entity affiliated…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 5.02(b). Resignation of Principal Officer Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of Telomir Pharmaceuticals, Inc. (the “Company”), effective on that date. Ms. Yanez’s resignation was a mutual separation from the Company and was…
Other Events Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir”), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines. The findings include improved mitochondrial ac…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.